全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
HPB Surgery  2013 

The Preoperative Assessment of Hepatic Tumours: Evaluation of UK Regional Multidisciplinary Team Performance

DOI: 10.1155/2013/861681

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction. In the UK, patients where liver resection is contemplated are discussed at hepatobiliary multidisciplinary team (MDT) meetings. The aim was to assess MDT performance by identification of patients where radiological and pathological diagnoses differed. Materials and Methods. A retrospective review of a prospectively maintained database of all cases undergoing liver resection from March 2006 to January 2012 was performed. The presumed diagnosis as a result of radiological investigation and MDT discussion is recorded at the time of surgery. Imaging was reviewed by specialist gastrointestinal radiologists, and resultswereagreedonby consensus. Results. Four hundred and thirty-eight patients were studied. There was a significant increase in the use of preoperative imaging modalities ( ) but no change in the rate of discrepant diagnosis over time. Forty-two individuals were identified whose final histological diagnosis was different to that following MDT discussion (9.6%). These included 30% of patients diagnosed preoperatively with hepatocellular carcinoma and 25% with cholangiocarcinoma of a major duct. Discussion. MDT assessment of patients preoperatively is accurate in terms of diagnosis. The highest rate of discrepancies occurred in patients with focal lesions without chronic liver disease or primary cancer, where hepatocellular carcinoma was overdiagnosed and peripheral cholangiocarcinoma underdiagnosed, where particular care should be taken. Additional care should be taken in these groups and preoperative multimodality imaging considered. 1. Introduction Cancer care in the UK has undergone a major change in recent years with the centralisation of care in a network of cancer centres [1]. This has led to the establishment of regional hepatopancreaticobiliary (HPB) units where patients in whom liver resection is contemplated are discussed at a multidisciplinary team (MDT) meeting in the presence of radiologists, oncologists, surgeons, and physicians. This is intended to provide greater clinical input into the diagnosis of the wide spectrum of disease processes for which liver resection is appropriate [2]. During the same period increasing awareness of the complimentary role of different imaging modalities in diagnosing liver disease [3–5] has led to many patients having multiple investigations prior to surgery. Although the accuracy of single imaging modalities including ultrasound [3, 6, 7], computerised tomography (CT) [3, 7, 8], magnetic resonance imaging (MRI) [3, 7, 9], and positron emission tomography (PET) [3, 8] scans in assessing

References

[1]  R. M. Charnley and S. Paterson-Brown, “Surgeon volumes in oesophagogastric and hepatopancreatobiliary resectional surgery,” British Journal of Surgery, vol. 98, no. 7, pp. 891–893, 2011.
[2]  “Improving outcomes in colorectal cancers improving outcomes in colorectal cancers,” National Institute for Health and Clinical Excellence, 2004, http://www.nice.org.uk/nicemedia/live/10895/28833/28833.pdf.
[3]  D. V. Sahani and S. P. Kalva, “Imaging the liver,” Oncologist, vol. 9, no. 4, pp. 385–397, 2004.
[4]  S. Bipat, M. S. van Leeuwen, J. N. M. Ijzermans, P. M. M. Bossuyt, J.-W. Greve, and J. Stoker, “Imaging and treatment of patients with colorectal liver metastases in the Netherlands: a survey,” Netherlands Journal of Medicine, vol. 64, no. 5, pp. 147–151, 2006.
[5]  K. O. Ong and E. Leen, “Radiological staging of colorectal liver metastases,” Surgical Oncology, vol. 16, no. 1, pp. 7–14, 2007.
[6]  J. Choi, “Imaging of hepatic metastases,” Cancer Control, vol. 13, no. 1, pp. 6–12, 2006.
[7]  W. Schima, C. Kulinna, H. Langenberger, and A. Ba-Ssalamah, “Liver metastases of colorectal cancer: US, CT or MR?” Cancer Imaging, vol. 5, pp. S149–156, 2005.
[8]  S. Bipat, M. S. van Leeuwen, E. F. I. Comans et al., “Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis,” Radiology, vol. 237, no. 1, pp. 123–131, 2005.
[9]  S. Blyth, A. Blakeborough, M. Peterson, I. C. Cameron, and A. W. Majeed, “Sensitivity of magnetic resonance imaging in the detection of colorectal liver metastases,” Annals of the Royal College of Surgeons of England, vol. 90, no. 1, pp. 25–28, 2008.
[10]  F. G. Fernandez, J. A. Drebin, D. C. Linehan et al., “Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET),” Annals of Surgery, vol. 240, no. 3, pp. 438–450, 2004.
[11]  R. H. Huebner, K. C. Park, J. E. Shepherd et al., “A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer,” Journal of Nuclear Medicine, vol. 41, no. 7, pp. 1177–1189, 2000.
[12]  R. C. Semelka, W. G. Cance, H. B. Marcos, and M. A. Mauro, “Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases,” Radiology, vol. 213, no. 1, pp. 86–91, 1999.
[13]  M. Kudo, “Diagnostic imaging of hepatocellular carcinoma: recent progress,” Oncology, vol. 81, no. 1, pp. 73–85, 2011.
[14]  A. G. Rockall, K. Planche, N. Power et al., “Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI,” Neuroendocrinology, vol. 89, no. 3, pp. 288–295, 2009.
[15]  O. M. Jones, M. Rees, T. G. John, S. Bygrave, and G. Plant, “Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection,” British Journal of Surgery, vol. 92, no. 9, pp. 1165–1168, 2005.
[16]  A. B. Cresswell, F. K. S. Welsh, and M. Rees, “A diagnostic paradigm for resectable liver lesions: to biopsy or not to biopsy?” HPB, vol. 11, no. 7, pp. 533–540, 2009.
[17]  W. R. Jarnagin, Y. Fong, A. Ky et al., “Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease,” Journal of the American College of Surgeons, vol. 188, no. 1, pp. 33–42, 1999.
[18]  A. Schepers, S. Mieog, B. B. van de Burg, J. van Schaik, G.-J. Liefers, and P. J. Marang-van de Mheen, “Impact of complications after surgery for colorectal liver metastasis on patient survival,” Journal of Surgical Research, vol. 164, no. 1, pp. e91–e97, 2010.
[19]  C. M. Patel, A. Sahdev, and R. H. Reznek, “CT, MRI and PET imaging in peritoneal malignancy,” Cancer Imaging, vol. 11, no. 1, pp. 123–139, 2011.
[20]  Y. E. Cheung, M. J. Kim, Y. N. Park, et al., “Varying appearances of cholangiocarcinoma: radiologic- pathologic correlation,” RadioGraphics, vol. 29, no. 3, pp. 683–700, 2009.
[21]  B. I. Choi, J. M. Lee, and J. K. Han, “Imaging of intrahepatic and hilar cholangiocarcinoma,” Abdominal Imaging, vol. 29, no. 5, pp. 548–557, 2004.
[22]  NICE, “Metastatic malignant disease of unknown primary origin: diagnosis and management of metastatic malignant disease of unknown primary origin,” 2010, http://www.nice.org.uk/nicemedia/live/13044/49848/49848.pdf.
[23]  J. Bridgewater and C. Imber, “New advances in the management of biliary tract cancer,” HPB, vol. 9, no. 2, pp. 104–111, 2007.
[24]  M.-F. Chen, “Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment,” Journal of Gastroenterology and Hepatology, vol. 14, no. 12, pp. 1144–1149, 1999.
[25]  J. P. Heiken, “Distinguishing benign from malignant liver tumours,” Cancer Imaging, vol. 7, pp. S1–S14, 2007.
[26]  T. Patel, “Cholangiocarcinoma-controversies and challenges,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 4, pp. 189–200, 2011.
[27]  E. Buc, M. Lesurtel, and J. Belghiti, “Is preoperative histological diagnosis necessary before referral to major surgery for cholangiocarcinoma?” HPB, vol. 10, no. 2, pp. 98–105, 2008.
[28]  B. Boland, A. Kim, N. Nissen, and S. Colquhoun, “Cholangiocarcinoma: aggressive surgical intervention remains justified,” American Surgeon, vol. 78, no. 2, pp. 157–160, 2012.
[29]  H.-C. Oh, M.-H. Kim, K. T. Lee et al., “Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma,” Journal of Gastroenterology and Hepatology, vol. 25, no. 12, pp. 1831–1837, 2010.
[30]  H. A. Edmondson, B. Henderson, and B. Benton, “Liver cell adenomas associated with use of oral contraceptives,” The New England Journal of Medicine, vol. 294, no. 9, pp. 470–472, 1976.
[31]  R. A. E. Clayton, D. L. Clarke, E. J. Currie, K. K. Madhavan, R. W. Parks, and O. J. Garden, “Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy,” Surgeon, vol. 1, no. 1, pp. 32–38, 2003.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133